Boston Autologous Islet Replacement Program: A New Diabetes Treatment

Several Boston-area hospitals have teamed up with Harvard Stem Cell Institute and biotech firm Semma Therapeutics to make personalized cell-based therapies that could lead to a new treatment for patients with type 1 diabetes (T1D). Read article here……

 

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.